SYF5ee2b686506946f985956f30b0f21a01Registry ID: 2026-526953-32-00|Not Yet RecruitingPhase 3
Loading search results
interventional
N/A
1 country
1
To assess the efficacy and safety of semaglutide in liver transplant candidates in terms of weight loss and metabolic control.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 10, 2026
Actual (reported)Percentage change in body weight from the start of treatment to the time of liver transplant, comparing semaglutide with standard treatment.
Total change in body weight from the start of treatment to the transplant.
Proportion of patients achieving a weight loss of ≥5%, ≥10% and ≥15% of body weight.
Change in BMI.
Changes in body composition: Visceral fat mass. Skeletal muscle mass (muscle index at L3 as measured by CT or DXA). Diagnosis of sarcopenia. Changes in metabolic parameters: Fasting glucose, HbA1c, HOMA-IR, total cholesterol, LDL, HDL, triglycerides.
Incidence of Early Graft Dysfunction (DPI/EAD) according to Olthoff’s criteria.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Wegovy 1 mg FlexTouch solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordFormulated product
Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordFormulated product
Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordFormulated product
Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Wegovy 1 mg FlexTouch solution for injection in pre-filled pen
Named ingredient: Semaglutide
View registry recordWegovy 0.5 mg FlexTouch solution for injection in pre-filled pen
Named ingredient: Semaglutide
View registry recordWegovy 2.4 mg FlexTouch solution for injection in pre-filled pen
Named ingredient: Semaglutide
View registry recordWegovy 0.25 mg FlexTouch solution for injection in pre-filled pen
Named ingredient: Semaglutide
View registry recordWegovy 1.7 mg FlexTouch solution for injection in pre-filled pen
Named ingredient: Semaglutide
View registry recordUniversity Clinical Hospital Virgen De La Arrixaca
Murcia, 30120, Spain
María Muñoz García
First Submitted
July 10, 2026
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Formulated product
Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
Contact the study team to confirm eligibility.